Status:
COMPLETED
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Lead Sponsor:
Medivation, Inc.
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in co...
Detailed Description
The proposed clinical trial will be a multi-center, randomized, open label, active control study in previously untreated patients with metastatic colorectal cancer aimed to evaluate the safety, tolera...
Eligibility Criteria
Inclusion
- Patient's age is 18 years or older, both genders.
- Patients with metastatic disease who are eligible for first line FOLFOX chemotherapy. Adjuvant or neoadjuvant given at least 12 months prior for non-metastatic disease is permitted.
- ECOG performance status ≤ 1
- At least 4 weeks from prior major surgery or radiotherapy.
- Life expectancy \>3 months
- Hematology: ANC ≥ 1.5X109/L; Platelets \>100x109/L.
- Adequate Renal function
- Adequate Hepatic functions
- Normal Cardiac function
Exclusion
- Patients who had adjuvant or neoadjuvant therapy for non-metastatic disease given within the last 12 months.
- Patients who had received Oxaliplatin within 12 months prior to diagnosis of metastatic disease.
- Patients on concurrent anti cancer therapy other than that allowed in the study.
- Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids
- Presence of clinically apparent or suspected brain metastasis.
- Patients who have had myocardial infarction, severe congestive heart failure, or significant arrhythmia within the past 6 months.
- Serious active infection at the time of pre-study screening.
- Active or history of autoimmune disorders/conditions.
- Women who are pregnant or lactating
- Concurrent active malignancy.
- Ascites, pleural effusions, or osteoblastic bone metastases as the only site of disease.
- Other prior malignancies, except for cured or adequately treated malignancies for which there has been no evidence of activity for more than 5 years.
- Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
- Patients with history of life threatening allergic reactions to food or drugs
- Patients with symptomatic peripheral neuropathy\> Grade 1.
- Known positive HIV, Hepatitis B surface antigen or Hepatitis C antibody.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT00890305
Start Date
May 1 2009
End Date
March 1 2013
Last Update
July 8 2015
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cancer Center of Huntsville, PC
Huntsville, Alabama, United States, 35801
2
University of South Florida
Tampa, Florida, United States, 33606
3
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10017
4
Signal Point Clinical Research Center
Middletown, Ohio, United States, 45042